Biomarker Development

Biomarkers are biological indicators that can help identify the presence or progression of diseases, such as Alzheimer’s Disease (AD). They play a crucial role in early detection, diagnosis, and monitoring the effectiveness of treatments.

At the Reddy Laboratory, we are focused on developing circulating microRNAs as peripheral biomarkers. By analyzing biofluids like serum, urine, and saliva from individuals across various age groups, including those with mild cognitive impairment, Alzheimer’s, ischemic stroke, and type 2 diabetes, we aim to define effective biomarkers for aging and cognitive decline.

Our research has highlighted microRNA-455-3p (miR-455-3p) as a promising therapeutic target and biomarker for Alzheimer’s Disease. Extensive studies indicate that miR-455-3p is involved in critical processes related to AD, such as amyloid precursor protein processing, oxidative stress management, mitochondrial health, and synaptic integrity. Its presence in the brains of AD patients and in various biological samples supports the potential of miR-455-3p as a valuable biomarker for diagnosing and monitoring the progression of Alzheimer’s.